Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Given Average Recommendation of “Moderate Buy” by Brokerages

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) has earned an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company.

Several equities research analysts have commented on BIOVF shares. Zacks Research upgraded Swedish Orphan Biovitrum to a “hold” rating in a research note on Thursday, May 7th. HC Wainwright started coverage on Swedish Orphan Biovitrum in a research report on Wednesday, May 6th. They set a “buy” rating on the stock.

Swedish Orphan Biovitrum Stock Performance

OTCMKTS BIOVF opened at $48.00 on Friday. The firm has a market cap of $17.09 billion, a P/E ratio of 160.00 and a beta of 0.36. The stock’s 50-day moving average is $46.24 and its 200-day moving average is $40.76. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.70 and a quick ratio of 0.47. Swedish Orphan Biovitrum has a one year low of $27.06 and a one year high of $48.00.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last released its earnings results on Tuesday, April 28th. The company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.38 by $0.07. The firm had revenue of $755.76 million for the quarter, compared to analysts’ expectations of $749.76 million. Swedish Orphan Biovitrum had a return on equity of 16.66% and a net margin of 3.37%. Sell-side analysts anticipate that Swedish Orphan Biovitrum will post 2.22 earnings per share for the current fiscal year.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.